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ron Oxide Magnetic
esonance Imaging
or Atherosclerosis
herapeutic Evaluation
till “Rusty?”*
ahi A. Fayad, PHD, Louai Razzouk, MD,
aren C. Briley-Saebo, PHD,
enkatesh Mani, PHD
ew York, New York
ulticenter, randomized, placebo-controlled “outcome” tri-
ls with long-term follow-up of thousands of patients are
urrently being used to evaluate new therapies for cardio-
ascular disease. Owing to improvements in risk factor
odifications as well as to the concomitant use of estab-
ished treatments, such as statins, leading to a drop in
linical event rates, it is projected that the number of
atients enrolled in trials may need to be increased to
eparate the effect of new therapies from those of established
nes. Recently, the JUPITER (Justification for the Use of
tatins in Primary Prevention: an Intervention Trial Eval-
ating Rosuvastatin) study (1) showed the importance of
erologic measures of inflammation. These new in-blood
See page 2039
arkers may, however, be insufficient when used alone as
redictive models of mortality and morbidity (2). Several
ecent cardiovascular trials have opted to use imaging
quantitative coronary angiography, carotid intima media
hickness with ultrasonography, coronary intravascular ul-
rasonography, and so forth) to measure the impact of
romising novel therapeutics (3). Validation of these in vivo
iagnostic imaging methods may allow for shorter
ollow-up times and eventually, for smaller patient popula-
ions tested.
Many imaging technologies focus primarily on changes in
uminal size or vessel wall area. New imaging methods that
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Mount Sinai School of Medicine, Translational and Molecular Imaging
nstitute, New York, New York.ocus on vessel wall composition, and relate to the under-
ying plaque pathogenesis, may provide useful information
ot readily available by standard morphometric measure-
ents. For example, noninvasive magnetic resonance imag-
ng (MRI) using ultrasmall superparamagnetic iron oxide
USPIO) particles has been shown to identify inflammatory
hanges by monitoring macrophage uptake, a major com-
onent of high-risk (vulnerable) plaques.
To date, there have been no published studies that show
orrelations between the dose of prescribed statin and
n vivo changes in macrophage distribution. The study by
ang et al. (4) in this issue of the Journal is the first
rospective molecular MRI study that tries to correlate the
n vivo effects of statin therapy on carotid plaque inflamma-
ion, as observed by MRI (5). The study found a significant
eduction from baseline in USPIO-enhanced MRI-defined
laque inflammation in the high-dose atorvastatin group at
oth 6 weeks and at 12 weeks after treatment. Such changes
ere not observed in the low-dose statin (i.e., atorvastatin
0 mg) group. These findings provide additional in vivo
vidence that high-dose statin (i.e., 80 mg) therapy might
ave a beneficial effect on plaque “stability.” Furthermore,
hese changes in USPIO-defined plaque inflammation
ould be observed within 6 weeks, a relatively short treat-
ent interval compared to the prolonged periods (years)
hat are required to observe changes in plaque burden. This
tudy may also indicate that reductions in plaque inflam-
ation may play an important role in the mechanism
nderlying the early beneficial effects of statins.
If adequately validated, USPIO-enhanced MRI method-
logy may be a useful imaging biomarker for the screening
nd assessment of therapeutic response to “anti-inflammatory”
nterventions in patients with carotid atherosclerotic lesions.
owever, before USPIO-MR can be routinely used for
ulticenter clinical testing, several issues with regard to the
urrent study need to be examined. The relatively small
atient group tested limits generalization of the dose-
esponse observed in this study. Although the authors
xhibit a weak correlation of the MRI data to the micro-
mboli count on transcranial Doppler, the study still does
ot correlate the MRI findings to any hard clinical end
oints.
Although the results of the ATHEROMA (Atorvastatin
herapy: Effects on Reduction of Macrophage Activity)
tudy (4) are exciting and show the potential of USPIO-
RI for longitudinal evaluation of plaque inflammation,
he utility of the method is counterbalanced by a lack of
uantitative rigor as compared with other current imaging
odalities. For example, the reproducibility and the repeat-
bility of vascular inflammation imaging using 18fluorode-
xyglucose (FDG) positron emission tomography (PET)
ith computed tomography (CT) is well validated and
stablished (6). Studies using FDG-PET/CT have shown a
eduction in inflammatory burden at 3 months after statin
reatment (7–9). Limited data are available, however, for
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Iron Oxide MRI for Evaluating Atherosclerosis June 2, 2009:2051–2linical studies using USPIO-MRI. As a result, aspects of
SPIO-MRI quantification need to be addressed before
sing this method in large multicenter clinical trials. The
uthors rely on visual observation and changes in signal
ntensity to determine USPIO uptake. However, differences
n patient positioning, coil inhomogeneities, noise, and
ther artifacts may all induce signal loss and may not be
ndicative of USPIO uptake. The conclusions obtained from
his study would be greatly strengthened by the addition of
alidated semiquantitative analyses. Moreover, imaging im-
rovements, such as the use of positive contrast or white-
arker data acquisition (gradient echo acquisition for su-
erparamagnetic particles, inversion recovery on-resonance
ater suppression, ultra short echo time, and so forth),
hich may be acquired within the same imaging session, are
xpected to improve image interpretation and data analysis
10). Finally, the nature of the atherosclerotic plaque, as
escribed on histology, is typically nonconcentric and may
ot benefit from a quadrants approach, as used in the
THEROMA study.
MRI does not expose the patient to radiation, thereby
llowing for long-term and serial monitoring. Unfortu-
ately, the USPIO (Sinerem, Guerbert, Roissy, France)
sed in the ATHEROMA study is currently not approved
y the Food and Drug Administration and is considered
nvestigational. Sinerem was originally developed as a con-
rast agent for the lymphatics and bone marrow (11,12); as
result, high lymphatic uptake is expected. Because the
ignal loss observed by USPIO is caused by dephasing of
iffusing water protons, blooming effects (or signal loss over
larger distance) may be observed. Owing to the proximity
f the lymphatics to the arterial wall, the data obtained
sing the quadrant analysis approach may become biased
nd/or skewed by lymphatic tissue included in any given
uadrant.
A potential clinical concern relates to the general use of
ron oxide particles for imaging of atherosclerotic plaques.
tudies have shown that macrophages metabolize iron
xides by degrading the iron core, with subsequent release of
oluble iron (13). Although most of this iron may be
aptured and stored as ferritin, there is a potential for the
elease of soluble iron (a known oxidant) into an inflamma-
ory environment. As a result, the metabolism of iron may
ead to the generation of superoxidases, which may further
romote the oxidation of low-density lipoprotein choles-
erol. Oxidized low-density lipoprotein cholesterol has been
mplicated in the pathogenesis of atherosclerosis and may
ead to plaque destabilization (14). Therefore, studies
hould be performed to ensure that metabolism of the
SPIO does not promote plaque destabilization if this
echnique is to become routinely used in clinical settings.
maging of inflammatory changes using USPIO also re-
uires 2 scans: a pre-contrast scan and a post-contrast
nfusion scan at each imaging time point.
K
pAlthough the current statin trial using noninvasive ca-
otid USPIO-MRI is interesting and unique, further studies
re required to determine the clinical applicability of this
ethodology for use as an end point in clinical trials. The
aluable ATHEROMA study presented by Tang et al. (4)
dds further momentum to the importance of using diag-
ostic molecular imaging in the development of future
ardiovascular therapies.
eprint requests and correspondence: Dr. Zahi A. Fayad,
ount Sinai School of Medicine, Cardiology, Box 1030, Imaging
cience Laboratories, One Gustave L. Levy Place, New York,
ew York 10029. E-mail: Zahi.Fayad@mssm.edu.
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